Disease · MONDO_0008433
small cell lung carcinoma
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. small cell lung carcinoma. Diseases, record MONDO_0008433. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0008433
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
Small cell lung cancer, lung oat cell carcinoma, lung small cell carcinoma, lung small cell neuroendocrine carcinoma, oat cell carcinoma of lung, oat cell carcinoma of the lung, oat cell lung carcinoma, small cell cancer of the lung, somatic, small cell carcinoma of lung, small cell carcinoma of the lung, small cell neuroendocrine carcinoma of lung, small cell neuroendocrine carcinoma of the lung, small-cell cancer of lung
- Open Targets
- Highest stage of its drugs
- Approval, for 11 of its 367 drugs, from ClinicalTrials.gov, DailyMed, EMA Human Drugs, FDA, PMDA and TTD
- Open Targets
Drugs367
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| ETOPOSIDE | CHEMBL44657 | Small molecule | Approval | DailyMed | 255 | 253 | 253 | Drugs and targets |
| DURVALUMAB | CHEMBL3301587 | Antibody | Approval | DailyMed | 72 | 71 | 71 | Drugs and targets |
| ATEZOLIZUMAB | CHEMBL3707227 | Antibody | Approval | EMA Human Drugs | 64 | 62 | 62 | Drugs and targets |
| TOPOTECAN | CHEMBL84 | Small molecule | Approval | EMA Human Drugs | 66 | 59 | 58 | Drugs and targets |
| LURBINECTEDIN | CHEMBL4297516 | Small molecule | Approval | ClinicalTrials.gov, DailyMed, FDA and TTD | 31 | 27 | 27 | Drugs and targets |
| TARLATAMAB | CHEMBL5095292 | Antibody | Approval | ClinicalTrials.gov, FDA and PMDA | 30 | 25 | 25 | Drugs and targets |
| SERPLULIMAB | CHEMBL4594550 | Antibody | Approval | EMA Human Drugs | 22 | 21 | 21 | Drugs and targets |
| TISLELIZUMAB | CHEMBL4297840 | Antibody | Approval | EMA Human Drugs | 21 | 20 | 20 | Drugs and targets |
| TOPOTECAN HYDROCHLORIDE | CHEMBL1607 | Small molecule | Approval | DailyMed | 22 | 19 | 19 | Drugs and targets |
| TRILACICLIB | CHEMBL3894860 | Small molecule | Approval | TTD | 7 | 6 | 6 | Drugs and targets |
1 to 10 of 367
See all 367 drugsTargets377
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| KDR | Vascular endothelial growth factor receptor | 18 | Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/3791 | Drugs and targets |
| FLT4 | Vascular endothelial growth factor receptor | 14 | Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/2324 | Drugs and targets |
| PDCD1 | Programmed cell death protein 1 | 14 | Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor | Approval | https://conductscience.org/library/genes/5133 | Drugs and targets |
| FLT1 | Vascular endothelial growth factor receptor | 13 | Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/2321 | Drugs and targets |
| KIT | Mast/stem cell growth factor receptor Kit | 13 | Stem cell growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/3815 | Drugs and targets |
| PDGFRB | Platelet-derived growth factor receptor | 13 | Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/5159 | Drugs and targets |
| TOP1 | DNA topoisomerase 1 | 12 | DNA topoisomerase I inhibitor | Approval | https://conductscience.org/library/genes/7150 | Drugs and targets |
| TUBA1A | Tubulin | 12 | Tubulin inhibitor; Tubulin stabiliser | Phase 3 | https://conductscience.org/library/genes/7846 | Drugs and targets |
| TUBA1B | Tubulin | 12 | Tubulin inhibitor; Tubulin stabiliser | Phase 3 | https://conductscience.org/library/genes/10376 | Drugs and targets |
| TUBA1C | Tubulin | 12 | Tubulin inhibitor; Tubulin stabiliser | Phase 3 | https://conductscience.org/library/genes/84790 | Drugs and targets |
1 to 10 of 377
See all 377 targetsTrials890
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 16 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01450761 | Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone | Phase 3 | 1,351 | 2016-07-18 | Small Cell Lung Carcinoma | CARBOPLATIN, CISPLATIN, ETOPOSIDE, IPILIMUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01928394 | A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors | Phase 1/2 | 1,163 | 2020-03-24 | Advanced or Metastatic Solid Tumors | COBIMETINIB, IPILIMUMAB, NIVOLUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03043872 | Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN) | Phase 3 | 987 | 2021-03-04 | Small Cell Lung Carcinoma Extensive Disease | CARBOPLATIN, CISPLATIN, DURVALUMAB, ETOPOSIDE, TREMELIMUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00363415 | Study of Pemetrexed and Carboplatin Compared With Etoposide Carboplatin to Treat Extensive-Stage Small Cell Lung Cancer | Phase 3 | 908 | 2009-10-06 | Small Cell Lung Cancer | CARBOPLATIN, PEMETREXED | Its record names the disease | ClinicalTrials.gov |
| NCT02538666 | An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy | Phase 3 | 907 | 2019-10-22 | Lung Cancer | IPILIMUMAB, NIVOLUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03033511 | A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU) | Phase 3 | 748 | 2020-12-21 | Small Cell Lung Cancer | ROVALPITUZUMAB TESIRINE | Its record names the disease | ClinicalTrials.gov |
| NCT00632853 | Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide | Phase 3 | 731 | 2023-06-12 | Lung Cancer | CARBOPLATIN, CISPLATIN, ETOPOSIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00940225 | Study of Cabozantinib (XL184) in Adults With Advanced Malignancies | Phase 2 | 730 | 2024-04-25 | Solid Tumors, Cancer | CABOZANTINIB | Its record names the disease | ClinicalTrials.gov |
| NCT03703297 | Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy | Phase 3 | 730 | 2025-08-01 | Small Cell Lung Cancer | DURVALUMAB, TREMELIMUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00045162 | S0124: Cisplatin Combined With Irinotecan or Etoposide For Extensive-Stage Small Cell Lung Cancer | Phase 3 | 671 | 2013-07-09 | Lung Cancer | CISPLATIN, ETOPOSIDE, IRINOTECAN HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 890
See all 890 trialsComparisons in its trials137
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| 10 MG/KG IPILIMUMAB + PLATINUM/ETOPOSIDE vs PLACEBO + PLATINUM/ETOPOSIDE: serious adverse events | 316 of 562 | 278 of 561 | 1,123 | NCT01450761 | Trial comparisons |
| Rovalpituzumab Tesirine/Dexamethasone vs Placebo: deaths from any cause | 226 of 372 | 201 of 376 | 748 | NCT03033511 | Trial comparisons |
| Rovalpituzumab Tesirine/Dexamethasone vs Placebo: serious adverse events | 157 of 368 | 87 of 373 | 741 | NCT03033511 | Trial comparisons |
| Cisplatin + Irinotecan vs Cisplatin + Etoposide: Confirmed and Unconfirmed Complete and Partial Responses. | 197 of 324 | 190 of 327 | 651 | NCT00045162 | Trial comparisons |
| Cisplatin + Irinotecan vs Cisplatin + Etoposide: serious adverse events | 107 of 321 | 31 of 327 | 648 | NCT00045162 | Trial comparisons |
| A Groups vs B Groups: Objective Response Rate | 268 of 389 | 115 of 196 | 585 | NCT04063163 | Trial comparisons |
| Group A vs Group B: deaths from any cause | 224 of 389 | 140 of 196 | 585 | NCT04063163 | Trial comparisons |
| Group A vs Group B: serious adverse events | 146 of 389 | 71 of 196 | 585 | NCT04063163 | Trial comparisons |
| Group A vs Group B: deaths from any cause | 251 of 284 | 256 of 285 | 569 | NCT02481830 | Trial comparisons |
| Group A vs Group B: serious adverse events | 183 of 282 | 171 of 265 | 547 | NCT02481830 | Trial comparisons |
1 to 10 of 137
See all 137 comparisons in its trialsPapers from its trials365
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0008433
GET https://conductscience.org/api/diseases/v1/MONDO_0008433/drugs?page=2